Novo Nordisk A/S (NYSE:NVO) Trading 3.1% Higher – Time to Buy?

Novo Nordisk A/S (NYSE:NVO) shares were up 3.1% during trading on Monday . The company traded as high as $39.88 and last traded at $39.7730. Approximately 23,690,162 shares traded hands during trading, a decline of 11% from the average daily volume of 26,533,146 shares. The stock had previously closed at $38.58.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal to sell Ozempic and Wegovy via Hims & Hers’ telehealth platform widens access to branded GLP‑1s, ends a legal feud and shifts patients away from compounded alternatives—potentially boosting prescription volumes and reducing off‑label/compounded competition. Hims & Hers deal
• Positive Sentiment: Planned manufacturing investment (Ireland expansion) to boost production capacity for oral GLP‑1s supports longer‑term supply and margin resilience as demand grows. Manufacturing expansion
• Neutral Sentiment: Analyst actions: TD Cowen cut NVO to Hold (lowered target to $42) and some peers trimmed expectations after guidance revisions—this tempers near‑term upside but reflects changed visibility rather than new product news. Analyst downgrade
• Negative Sentiment: FDA warning letter citing failures in post‑marketing adverse event reporting (including alleged unreported semaglutide‑linked serious events) raises regulatory/compliance risk and has triggered media scrutiny and investor concern about reporting practices and potential enforcement. Novo says it’s taken corrective actions and FDA made no finding on product quality. FDA warning letter
• Negative Sentiment: Investor litigation: a Pomerantz class‑action investigation was announced, increasing legal risk and potential distraction for management. Investor investigation
• Negative Sentiment: Competitive/pipeline pressure: trial data from rivals and analyst commentary that the pipeline may not fully offset semaglutide loss‑of‑exclusivity (LOE) risk are weighing on mid/long‑term revenue outlook and were cited in recent “neutral” analyst stances. Competitive pipeline risk
• Negative Sentiment: Regulatory environment in large markets: India’s warning to drugmakers against direct or surrogate weight‑loss advertising could constrain marketing and uptake in a fast‑growing market if similar restrictions spread. India ad guidance

Analysts Set New Price Targets

A number of research firms recently issued reports on NVO. The Goldman Sachs Group restated a “neutral” rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Citigroup began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. Four research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $49.93.

Novo Nordisk A/S Stock Performance

The firm has a 50 day moving average of $50.93 and a 200-day moving average of $52.11. The company has a market cap of $173.31 billion, a P/E ratio of 11.19 and a beta of 0.73. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The business had revenue of $12.43 billion during the quarter, compared to analyst estimates of $11.97 billion. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Announces Dividend

The company also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be issued a $1.2751 dividend. This represents a dividend yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s payout ratio is presently 23.63%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. True Wealth Design LLC boosted its stake in shares of Novo Nordisk A/S by 209.8% during the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after purchasing an additional 300 shares in the last quarter. Guerra Advisors Inc bought a new position in Novo Nordisk A/S in the third quarter worth approximately $25,000. Godfrey Financial Associates Inc. purchased a new stake in Novo Nordisk A/S during the fourth quarter worth $25,000. WealthCollab LLC lifted its holdings in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares during the period. Finally, American National Bank & Trust bought a new stake in Novo Nordisk A/S during the 4th quarter valued at $28,000. 11.54% of the stock is currently owned by institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.